🩺 Real‑world diabetes research—done right
From risk prediction in metabolic syndrome to cost comparisons in insulin delivery, diabetes care needs rigour, relevance, and real‑world insight.
🔹 In 2024, we helped show how metabolic syndrome traits raise the risk of liver outcomes in Type 2 diabetes: Read here
🔹 In 2022, we analysed Nordic RWE showing empagliflozin’s impact on cardiorenal outcomes and mortality in Sweden: Read here
🔹 In 2019, we assessed real‑world costs of insulin pumps vs daily injections in Type 1 diabetes using Swedish registry data: Read here
All public studies; just a small window into our broader work in diabetes.
💡How are you using real‑world data in diabetes care or access strategy?
